Sacituzumab Govitecan—another ADC more commonly known for its activity in breast and urothelial cancers—targets trophoblast cell surface antigen (TROP-2) that is expressed in multiple cancers but mostly absent in normal tissues, making it an ideal target for cancer-directed treatments. The gene discussed is TACSTD2; the disease is cancer.